ConductScience.org, home

Paper42872032PubMed

Metabolic dysfunction-associated steatotic liver disease (MASLD) versus metabolic dysfunction and alcohol-associated steatotic liver disease (Met-ALD), do the differences matter in clinical practice?

Byrne CD. Hepatobiliary Surg Nutr, 2026.

Cite this record

ConductScience Library. Metabolic dysfunction-associated steatotic liver disease (MASLD) versus metabolic dysfunction and alcohol-associated steatotic liver disease (Met-ALD), do the differences matter in clinical practice? Papers, record 42872032. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42872032

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Metabolic dysfunction-associated steatotic liver disease (MASLD) versus metabolic dysfunction and alcohol-associated steatotic liver disease (Met-ALD), do the differences matter in clinical practice?
Journal
Hepatobiliary Surg Nutr
Year
2026
Publication types
Editorial, Comment
Revised in PubMed
2026-10-15

Source PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Byrne CDChristopher Dhttps://orcid.org/0000-0001-6322-7753

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment on40953570
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis.
https://conductscience.org/library/papers/40953570

Source PubMed

Download CSV of comments and corrections

References16

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139548715Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD: A UK Biobank Study.Liver Int2025https://conductscience.org/library/papers/39548715PubMed
220223875Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study.BMJ2010https://conductscience.org/library/papers/20223875PubMed
325920090NAFLD: a multisystem disease.J Hepatol2015https://conductscience.org/library/papers/25920090PubMed
437363821A multisociety Delphi consensus statement on new fatty liver disease nomenclature.Hepatology2023https://conductscience.org/library/papers/37363821PubMed
540316227Longitudinal Clinical Outcomes and Mortality from Steatotic Liver Disease: A Meta-Analysis.Am J Med2025https://conductscience.org/library/papers/40316227PubMed
627543837The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.Hepatology2016https://conductscience.org/library/papers/27543837PubMed
740802944Metabolic Dysfunction-Associated Steatotic Liver Disease.N Engl J Med2025https://conductscience.org/library/papers/40802944PubMed
830180285Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States.Hepatology2019https://conductscience.org/library/papers/30180285PubMed
938228377MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.Gut2024https://conductscience.org/library/papers/38228377PubMed
1040414560Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes.Metabolism2025https://conductscience.org/library/papers/40414560PubMed
1141652552Association between steatotic liver disease (MASLD, met-ALD, and ALD) with preserved ratio impaired spirometry: a population-based study.BMC Pulm Med2026https://conductscience.org/library/papers/41652552PubMed
1220223873Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies.BMJ2010https://conductscience.org/library/papers/20223873PubMed
1340953570
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis.
Lancet Gastroenterol Hepatol2025https://conductscience.org/library/papers/40953570PubMed
1436063967Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease.J Hepatol2023https://conductscience.org/library/papers/36063967PubMed
1541368474Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?Curr Hepatol Rep2025https://conductscience.org/library/papers/41368474PubMed
1619766548Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease.Dig Liver Dis2010https://conductscience.org/library/papers/19766548PubMed

Download CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42872032

GET https://conductscience.org/api/papers/v1/42872032/authors